Drug Profile

CMDE 002

Alternative Names: CMDE-002

Latest Information Update: 19 Sep 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Zhejiang Shimai Pharmaceutical
Class Antineoplastics; Bispecific antibodies; Immunotherapies
Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

19 Sep 2025 Discontinued - Preclinical for Solid tumours in China (Parenteral), before September 2025 (Zhejiang Shimai Pharmaceutical pipeline, September 2025)
19 Sep 2025 Discontinued - Preclinical for Solid tumours in USA (Parenteral), before September 2025 (Zhejiang Shimai Pharmaceutical pipeline, September 2025)
13 Jun 2022 Zhejiang Shimai Pharmaceutical intends to submit a IND application for Solid tumour in China and USA in 2022 (Zhejiang Shimai Pharmaceutical pipeline, June 2022)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com